China Heal Plus

HEALTHCARE UPDATE

EMA Confirms Refusal of Yartemlea After Re-examination

By China Heal Plus · Updated

The European Medicines Agency confirmed its recommendation to refuse Yartemlea (narsoplimab) after a re-examination on October 15. The proposed use concerned a serious complication of donor stem-cell transplantation in adults and children age two and older.

Concerns About the Clinical Evidence Remain

EMA’s explanation, published October 16, says the main study involved 28 adults and did not compare the medicine with another treatment or placebo. Participants also received other medicines, making the observed effects difficult to interpret. The committee reviewed additional information and consulted transplant specialists, but concluded that its concerns remained unresolved.

The complication, called transplant-associated thrombotic microangiopathy, involves damage to small blood vessels and can affect organ function. The new opinion follows the committee’s initial negative recommendation in June. It is a European regulatory assessment, not a determination of an individual patient’s treatment.

Sources: [1], [2]

Preparing for a Specialist Review

For a planned second opinion, our practical suggestion is to organize the transplant summary, recent test results and previous specialist assessments. Ask the reviewing transplant team to explain which evidence and local access rules apply to the case. Urgent complications need attention from the treating team without waiting for a remote records review.

Sources and data notes

  1. EMA: Yartemlea re-examination and reasons for refusal

    Opinion adopted October 15, 2026; revised questions-and-answers document first published October 16. Original checked October 17. The page footer retains an older July update date; the event date is verified in the overview and product details. This is a recommendation to refuse authorization, not a new treatment approval.

  2. EMA: October 12–15 CHMP meeting highlights

    October meeting summary checked October 17, 2026. Confirms the re-examination outcome. Record-preparation suggestions are our editorial interpretation; they do not offer individual treatment advice or establish access in another country.

Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.

All healthcare updates